S. Dougherty

发表

Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.

S. Verstovsek, A. Vannucchi, C. Harrison, 2022, Future oncology.

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.

K. Götze, P. Greenberg, A. Verma, 2015, The Lancet. Haematology.

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.

E. Vellenga, D. Steensma, P. Fenaux, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

D. Niederwieser, R. Hoffman, A. Vannucchi, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, Placebo-Controlled, Phase I/II Trial Of The Thrombopoietin Receptor Agonist Eltrombopag In Thrombocytopenic Patients With Advanced Myelodysplastic Syndromes Or Acute Myeloid Leukemia — A Subgroup Analysis Of Patients Receiving Concomitant Anticancer Therapy

K. Götze, P. Greenberg, A. Verma, 2013 .

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

D. Niederwieser, R. Hoffman, A. Reiter, 2018, Blood.

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

S. Verstovsek, A. Vannucchi, S. Koschmieder, 2022, Blood.

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

S. Verstovsek, R. Mesa, A. Vannucchi, 2020 .

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

E. Vellenga, D. Steensma, P. Fenaux, 2019, Blood.

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

P. Fenaux, A. Raza, M. Sekeres, 2022, Blood.

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

E. Vellenga, P. Fenaux, S. Thépot, 2021, Blood.

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

M. Sekeres, U. Platzbecker, V. Santini, 2023, The Lancet.